Pharma News

The FDA has granted Breakthrough Therapy designation to Vaxcyte for its VAX-24, an investigational 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease, a group of bact...

Biogen’s efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China’s InnoCare last year for $...

The FDA has approved Roche’s Actemra (tocilizumab) for intravenous treatment of hospitalized adults who have COVID-19 and are receiving systemic corticosteroids and require supplemental oxygen, ...

The FDA has granted accelerated approval to Roche’s Lunsumio (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or resistant follicular lymphoma (a common type of non-Hodgkin ...

First direct evidence of diminished 5-HT release proves hypothesis, according to a new analysis published in Biological Psychiatry.

Researchers at Karolinska Institutet have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.  ...

The FDA has granted approval to Gilead Sciences’ Sunlenca (lenacapavir) for treatment of adults with human immunodeficiency virus (HIV) type 1 whose HIV infections can’t be treated with other ...

LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.

Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems. ...

Amid a massive surge in Covid cases, China's National Health Commission has now decided not to publish daily Covid data. Hospitals and morgues in China are fully packed as Covid cases are sweeping ...

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen. ...

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment. ...